Multi-Omics Approaches to Neuroscience Research Using Blood Biospecimens

Integrated Multi-Omics Strategies in Neurodegeneration Research

Neurodegenerative disease complexity defies reductionist approaches focusing on single molecules or pathways across research institutions throughout the United States. Disease pathogenesis involves intricate interactions among genetic risk factors, protein misfolding cascades, metabolic dysfunction, immune activation, synaptic perturbations, and vascular abnormalities manifesting across molecular, cellular, and systems levels simultaneously.

Multi-omics research strategies integrate genomics, transcriptomics, proteomics, metabolomics, and lipidomics from blood biospecimens enabling systems-level understanding of disease mechanisms. Novel therapeutic targets emerge from pathway analyses. Predictive biomarkers combine multiple molecular readouts. Patient stratification approaches tailor interventions to specific molecular endotypes, improving treatment outcomes.

High-throughput omics technologies are becoming increasingly accessible and cost-effective for neuroscience applications. Researchers across academic medical centers, biotechnology companies, and government laboratories require comprehensive biospecimen collections supporting integrated analyses. These capture disease complexity through complementary molecular profiling modalities from patients with confirmed neurodegenerative diagnoses throughout the natural history of progression.

Blood-based multi-omics research leverages peripheral blood sampling accessibility, enabling serial collections. Longitudinal molecular trajectories document disease evolution from preclinical through symptomatic stages.

Proteomics: Plasma and Serum Protein Profiling

Plasma and serum contain thousands of proteins reflecting biological processes. Mass spectrometry-based proteomics quantifies protein concentrations. Alzheimer’s plasma proteomes reveal changes in amyloid processing, inflammatory pathways, and synaptic proteins.

Metabolomics: Small Molecule Profiling

Metabolomics measures metabolites in plasma and serum reflecting metabolic pathway activities. Brain metabolism depends on glucose utilization and lipid homeostasis. Neurodegenerative diseases show metabolic dysregulation detectable peripherally.

Key Variables Affecting Multi-Omics Quality

Factors impacting reproducibility:

Biological Variables:

• Age effects on baseline profiles requiring age-matching
• Sex differences in metabolism and expression
• BMI/obesity affecting metabolic markers
• Circadian timing for rhythm-sensitive analytes
• Recent infection state producing acute signatures
• Diet patterns and recent intake
• Exercise habits modulating omics layers

Technical Variables:

• Collection tube types and anticoagulant selection
• Blood volume and processing yield
• Centrifugation protocols
• Storage time before processing
• Freeze-thaw cycle number
• Batch effects across collection sites
• Seasonal collection timing

Sanguine Bio Multi-Omics Solutions

Sanguine Bio provides premium-quality neuroscience biospecimens with comprehensive genomic annotation. Our direct-to-donor model ensures access to diverse patient populations with confirmed neurodegenerative diagnoses.

Custom collection services address unique multi-omics requirements. We design protocols matching specific needs. Sample collection occurs at optimal timepoints. Processing follows validated SOPs maintaining integrity across all omics platforms. Quality control ensures specimen suitability.

Access to hard-to-find populations enables longitudinal cohort assembly. Preclinical patients provide early disease insights. Treatment-naive individuals establish baseline profiles. Longitudinally followed cohorts document progression trajectories across the United States.

From study design through receipt of samples, we optimize biospecimens for multi-omics success. Consultation services guide study planning. Protocol development matches analytical platforms. Collection coordination ensures timing consistency.

Ethical Sourcing and Regulatory Compliance

All Sanguine biospecimens meet rigorous ethical standards. Informed consent processes follow federal regulations and institutional requirements. IRB approval documentation accompanies collections. Donor privacy protection satisfies HIPAA standards. Ethical review ensures research appropriateness.

Bio-Banking Standards and Quality

Comprehensive quality management systems ensure specimen integrity. Collection SOPs standardize procedures. Processing protocols maintain consistency. Storage monitoring tracks temperature continuously. Documentation systems enable full traceability across the United States.

Advancing Neuroscience Through Premium Biospecimens

Multi-omics research transforms neurodegenerative disease understanding. Integrated approaches reveal disease complexity. Systems biology insights identify therapeutic targets. Precision medicine strategies emerge from molecular profiling, enabling personalized interventions.

High-quality biospecimens with comprehensive genomic annotation accelerate discoveries. Researchers accessing appropriate materials advance faster. Study validity improves with proper specimens. Regulatory acceptance depends on documented quality throughout research programs.

Check Our Inventory of neuroscience biospecimens supporting your multi-omics investigations.

References

1. Blenn C, et al. Multiomics studies investigating the molecular regulation of Alzheimer’s disease. Neurobiol Dis. 2022;168:105711. Multiomics studies investigating the molecular regulation of Alzheimer’s disease
2. Johnson ECB, et al. Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism. Nat Med. 2020;26(5):769-780. Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism
3. Nativio R, et al. An integrated multi-omics approach identifies epigenetic alterations associated with Alzheimer’s disease. Nat Genet. 2020;52(10):1024-1035. An integrated multi-omics approach identifies epigenetic alterations associated with Alzheimer’s disease
4. Ciryam P, et al. A transcriptome and translatomic analysis of Drosophila insulin-producing cells. Cell Rep. 2013;3(5):1476-1489. A transcriptome and translatomic analysis of Drosophila insulin-producing cells
5. Arnold M, et al. Sex and APOE ε4 genotype modify the Alzheimer’s disease serum metabolome. Nat Commun. 2020;11(1):1148. Sex and APOE ε4 genotype modify the Alzheimer’s disease serum metabolome
6. Habékost M, et al. Multi-omic blood-based biomarkers for Alzheimer’s disease: A systematic review and meta-analysis. Alzheimers Dement. 2023;19(4):1643-1654. Multi-omic blood-based biomarkers for Alzheimer’s disease: A systematic review and meta-analysis
7. Shigemizu D, et al. Identification of potential blood biomarkers for early diagnosis of Alzheimer’s disease through RNA sequencing analysis. Alzheimers Res Ther. 2020;12(1):87. Identification of potential blood biomarkers for early diagnosis of Alzheimer’s disease through RNA sequencing analysis
8. Toledo JB, et al. Metabolic network failures in Alzheimer’s disease. Alzheimers Dement. 2017;13(9):965-984. Metabolic network failures in Alzheimer’s disease
9. Tynkkynen J, et al. Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia. Alzheimers Dement. 2018;14(6):723-733. Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia
10. Proitsi P, et al. Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer’s disease. Transl Psychiatry. 2015;5(1):e494. Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer’s disease
11. Montine TJ, et al. Multiplatform metabolomics for discovery of Alzheimer’s biomarkers. Alzheimers Dement. 2021;17(10):1693-1706. Multiplatform metabolomics for discovery of Alzheimer’s biomarkers
12. Robinson JL, et al. An atlas of human metabolism. Sci Signal. 2020;13(624):eaaz1482. An atlas of human metabolism
13. Whelan CD, et al. Multi-omic integration reveals cell-type-specific molecular networks in Alzheimer’s disease. Nat Neurosci. 2022;25(11):1564-1578. Multi-omic integration reveals cell-type-specific molecular networks in Alzheimer’s disease
14. Guo T, et al. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Mol Neurodegener. 2020;15(1):40. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
15. Higginbotham L, et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease. Sci Adv. 2020;6(43):eaaz9360. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease

Sanguine supplies research-grade human serum for studies like this.